04Dec
04Dec
Man Visually Impaired for 17 Years Sees Girlfriend for the First Time and Proposes to Her
Brittney Reed and her boyfriend Hunter Tribe looking into each other’s eyes while he is wearing eSight glasses. Tribe has a degenerative eye condition called Stargardt's disease. This leads to near-total blindness where they can still see peripherally, but this sight is still hazy. This clueless boyfriend had no idea that his partner had written into the ""Rachael Ray"" show, which habitually helps those struggling with eyesight issues. She asked if they could help Tribe see with a pair of...
03Dec
Core vendors seek to eliminate barriers in bank-fintech partnerships
The Milford Bank is a 149-year-old community institution in Connecticut trying to attract a younger audience. But there are limits to how extensively it can enhance its technological capabilities in-house or research, test and integrate products from potential fintech partners. With the help of Fiserv, its core provider, the $550 million-asset bank incorporated into its offerings the services of FutureFuel.io, which helps users manage their student debt. Fiserv has been quietly engineering connections between its bank clients and fintechs that...
03Dec
The donation of sight
North Country Association for the Visually Impaired Executive Director Amy Kretser tries on a pair of Tina Leonard’s eSight glasses on Nov. 18. Leonard, a Lake Placid real estate broker who died in September at the age of 63, used the $10,000 glasses for a short time until she lost all of her sight. Kretser isn’t sure exactly how the eSight glasses will be used. Perhaps they will be a “demo” model for people who are visually impaired to try...
03Dec
What will tomorrow’s Covid-19 vaccines be like?
The first generation of Covid-19 vaccines was developed in record time. But now scientists have grander plans – for more potent immunity, easier transport, and mutation-proofing... While Zion, an entrepreneur and chief executive of a small start-up called Akston Biosciences, was personally relieved that the tide was turning against the global pandemic, he faced the unenviable task of trying to convince his employees that their hard graft had not been in vain. Read more >>
03Dec
The Boston Globe Names Wasabi Technologies a Top Place to Work for 2021
Wasabi Technologies, the hot cloud storage company, today announced it has been named one of the Top Places to Work in Massachusetts in the 14th annual employee-based survey project from The Boston Globe. The Top Places to Work 2021 issue publishes online at Globe.com/TopPlaces on the night of December 1 and in Globe Magazine on December 5. Read more >>
03Dec
ZetrOZ Systems Expands Patient Access for Sustained Acoustic Medicine Treatment
ZetrOZ's sam® is the only FDA-cleared, long-duration, home-use, ultrasound treatment system, with over 30 peer-reviewed studies showing it effectively increases nutrient transport, relieves pain, restores function, and returns patients back to work, sports and other daily activities. Its continuous ultrasound therapy promotes injury healing to deep tissue by inhibiting inflammation and increasing the rate of tissue regeneration, angiogenesis, and nutrient exchange. sam® was designed for easy, long-term home use. Read more >>
02Dec
Pyramid Biosciences’ $864 Million Licensing Deal
Clinical-stage biotechnology company Pyramid Biosciences, Inc. announced the development of a global licensing deal for two cancer therapies worth up to $846 million. The licensing agreement with South Korea-based biotechnology company Voronoi, Inc. will bring a novel monopolar spindle1 (MPS1) called VRN-08 and second undisclosed asset into Pyramid Bioscience’s portfolio of precision oncology therapeutics. MPS1 is involved in core-of-tumor cell division. The novel inhibitor VRN-08 selectively blocks this process, ultimately leading to tumor cell death. Founded in 2015, Waltham, Mass.-based...
02Dec
Groton biotech firm working on much-needed drug to treat stroke, brain injuries
A small drug development company that moved its headquarters from Cambridge, Mass., to the BioCT Innovations Commons on Shennecossett Road last year is aiming to have a huge impact on the treatment of strokes and brain injuries. Co-founded by William Korinek of Stonington, who spent nearly a decade at Pfizer, Astrocyte Pharmaceuticals expects to launch a phase one clinical trial of its leading drug candidate in the first half of 2022. Read more >>
01Dec